Please assess the completion status of the following clinical trial:

Trial Title: NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older.~2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation \> 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, CPK MB or both).~   Chest pain syndrome can extend to more than 3 days prior to admission if its course is consistent with transient/intermittent ischemia rather than symptoms that are continuous suggesting ongoing infarction extending beyond 3 days.~3. Successful stent placement and reperfusion within 3 days of chest pain onset and with TIMI Flow score of 2 or 3 and infarct related artery (IRA) with \<20% stenosis after revascularization.~4. Wall motion abnormality associated with the target lesion~5. NYHA heart failure class I, II or III.~6. Study entry LVEF \<48% determined by CMR no sooner than 96 hours from stent placement.~7. Able to provide informed written consent and willing to participate in all required study follow-up assessments.~8. Subjects must have an INR ≤ 2.0 within 2 days of the bone marrow collection.~9. Subjects must have a Hgb ≥ 10 grams/dL, WBC ≥ 3500 cells/mm3, a platelet count ≥ 100,000 cells/mm3, serum creatinine ≤ 2.5, and total bilirubin ≤ 2.0 within 7 days of the bone marrow collection or by end of screening phase.~10. Expected survival of at least one year.~11. Females of child bearing potential agree to use birth control (barrier method accepted) for one month post bone marrow harvest.~EXCLUSION CRITERIA~1. Continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.~2. Subjects in cardiogenic shock (systolic pressure \< 80mm/Hg, on vasopressors, or intra-aortic counterpulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.~3. Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc).~4. Subjects receiving warfarin who have an INR \>2 or with major bleeding requiring active transfusion support.~5. Subjects who require continuous anticoagulation during the time when the bone marrow harvest is scheduled, as heparin must be discontinued for 4 hours prior to and 24 hours after bone marrow harvest procedure. (See Appendix VII.)~6. Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.~7. Subjects with known severe immunodeficiency states (AIDS).~8. Cirrhosis requiring active medical management.~9. Malignancy requiring active treatment (except basal cell skin cancer).~10. Subjects with documented active alcohol and /or other substance abuse.~11. Females of child bearing potential unless a pregnancy test is negative within 7 days of the mini-bone marrow harvest.~12. Re-occlusion of the IRA prior to the infusion procedure.~13. Planned revascularization intervention during the next 6 months (A second PCI can be performed if done prior to qualifying CMR at least 96 hours post primary PCI).~14. Participation in an ongoing investigational trial.~15. Active or suspected bacterial infection requiring systemic intravenous antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NBS10 (Type: EXPERIMENTAL): active treatment - CD34+ cells
- placebo (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).